We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+15.77%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$113M
AUM Growth
+$12.4M
Cap. Flow
+$8.07M
Cap. Flow %
7.13%
Top 10 Hldgs %
79.99%
Holding
35
New
11
Increased
3
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$8.05M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$3.67M
3
OPTN
OptiNose
OPTN
+$3.34M
4
CTLT
CATALENT, INC.
CTLT
+$2.72M
5
IMTX icon
Immatics
IMTX
+$2.59M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$4.92M
2
ADMA icon
ADMA Biologics
ADMA
+$3.91M
3
HCSG icon
Healthcare Services Group
HCSG
+$3.6M
4
LNTH icon
Lantheus
LNTH
+$3.08M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.83M

Sector Composition

Rank Sector Weight
1 Healthcare 82.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
$19.1M 16.89%
+50,000
New +$19.2M
ADMA icon
2
ADMA Biologics
ADMA
$2.17B
$15.5M 13.71%
4,000,000
-1,269,155
-24% -$3.91M
IMCR icon
3
Immunocore
IMCR
$1.73B
$11.8M 10.38%
205,974
-87,411
-30% -$4.92M
TELA icon
4
TELA Bio
TELA
$42.1M
$8.58M 7.58%
746,087
– –
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.83M 6.92%
68,829
– –
LNTH icon
6
Lantheus
LNTH
$6.59B
$7.64M 6.75%
150,000
-50,000
-25% -$3.08M
OPTN
7
DELISTED
OptiNose
OPTN
$6.47M 5.72%
233,124
+88,019
+61% +$3.34M
HRTX icon
8
Heron Therapeutics
HRTX
$69.1M
$6.25M 5.52%
+2,500,000
New +$8.05M
QIPT
9
DELISTED
Quipt Home Medical
QIPT
$3.77M 3.33%
800,000
– –
PNT
10
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$3.6M 3.18%
+494,136
New +$3.67M
INSP icon
11
Inspire Medical Systems
INSP
$1.75B
$2.52M 2.23%
+10,000
New +$2.13M
THC icon
12
Tenet Healthcare
THC
$21B
$2.44M 2.16%
+50,000
New +$2.31M
CTLT
13
DELISTED
CATALENT, INC.
CTLT
$2.25M 1.99%
+50,000
New +$2.72M
IMTX icon
14
Immatics
IMTX
$1.33B
$2.18M 1.92%
+250,000
New +$2.59M
EDSA icon
15
Edesa Biotech
EDSA
$50.2M
$1.92M 1.7%
+126,984
New +$945K
HCSG icon
16
Healthcare Services Group
HCSG
$1.51B
$1.53M 1.35%
127,252
-272,748
-68% -$3.6M
JSPR icon
17
Jasper Therapeutics
JSPR
$25.8M
$1.37M 1.21%
321,904
– –
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
$1.29M 1.14%
+10,000
New +$1.29M
SNDA icon
19
Sonida Senior Living
SNDA
$1.87B
$1.04M 0.91%
82,832
– –
COLL icon
20
Collegium Pharmaceutical
COLL
$883M
$1.03M 0.91%
44,448
+4,491
+11% +$90.6K
RZLT icon
21
Rezolute
RZLT
$444M
$828K 0.73%
400,000
– –
BLU
22
DELISTED
BELLUS Health Inc.
BLU
$822K 0.73%
100,000
– –
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.13B
$789K 0.7%
20,000
– –
ALIM
24
DELISTED
Alimera Sciences
ALIM
$699K 0.62%
257,753
+30,151
+13% +$128K
CFMS
25
DELISTED
Conformis, Inc. Common Stock
CFMS
$685K 0.6%
206,256
– –
1
2

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return

Velan Capital Investment Management's Q4 2022 Portfolio in Review

As of Q4 2022, Velan Capital Investment Management held 35 positions worth $113M, up 12% from $101M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Velan Capital Investment Management deployed $8.07M of net new capital in Q4 2022, opening 11 new positions and adding to 3 existing holdings. Its largest new stake was Heron Therapeutics: 2,500,000 shares worth $6.25M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Immunocore, an estimated $4.92M trimmed.

  • Velan Capital Investment Management's largest Q4 2022 buy was Heron Therapeutics: 2,500,000 shares worth $6.25M.
  • Velan Capital Investment Management added most to OptiNose in Q4 2022, an estimated $3.34M increase.
  • Velan Capital Investment Management's biggest Q4 2022 reduction was Immunocore, cutting an estimated $4.92M.
  • Velan Capital Investment Management fully exited BioCryst Pharmaceuticals in Q4 2022, selling an estimated $2.83M.
  • Velan Capital Investment Management's ten largest holdings make up 80% of its $113M portfolio in Q4 2022.
  • Velan Capital Investment Management opened 11 new positions and closed 7 in Q4 2022.
  • Velan Capital Investment Management's portfolio value rose 12% quarter-over-quarter to $113M.

Based on Velan Capital Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.